FAKTOR-OPTIONSSCHEIN - GENMAB | Market Closed - Börse Stuttgart 11:49:34 25/06/2024 pm IST | ||
| 12.98 EUR | -0.15% |
|
| Current month | +15.69% | ||
| 1 month | +16.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 12.98 | -0.15% |
| 24/24/24 | 13 | +2.77% |
| 21/24/21 | 12.65 | -1.48% |
| 20/24/20 | 12.84 | -4.18% |
| 19/24/19 | 13.4 | +3.08% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 11:49 pm IST
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | MG1KCD |
| ISIN | DE000MG1KCD4 |
| Date issued | 03/04/2024 |
| Strike | 2,707 kr |
| Maturity | Unlimited |
| Parity | 9.42 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.52 € |
|---|---|
| Lowest since issue | 9.99 € |
| Spread | 0.21 € |
| Spread % | 1.59% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
